Based in Palo Alto, California, Cognoa provides child assessment and developmental support services. Established in 2013, Cognoa serves customers nationwide and designs assessment tools through a team of technology and child development researchers at esteemed institutions such as Harvard Medical School. Cognoa also received a showcase at the 2015 annual health and medicine conference TEDMED. Available for iOS and Android devices, the application is designed to detect developmental delays in children 18 months to 6 years. Assessment tools utilize information and/or video supplied by parents to evaluate a child’s current development and estimate the potential risk for issues such as autism and developmental delay. Cognoa also offers support services to help children improve or continue their progress. Cognoa’s technology is backed by five years of research and validated data from over 10,000 children. Cognoa's scientific founder Dennis Wall, PhD, led the studies, and applications were designed using machine learning algorithms, enabling the detection of meaningful data patterns and honing in on specific behaviors from diagnostic standards used to identify developmental delays.
Based in Palo Alto, Cognoa, a software-as-a-medical device company focusing on pediatric behavioral health, provides employers with a technologically enhanced method of supporting the needs of their employees who have children. Cognoa’s app allows employees to receive timely behavioral health recommendations based on their child’s unique developmental trajectory. Providing a supportive service…
Cognoa App Streamlines Diagnosis of Developmental Delays
Five years of clinical research conducted at Harvard Medical School resulted in the creation of Cognoa’s app, which helps to screen for developmental delays in early childhood. The app, which is now available to parents through partnering insurance providers and employers, can be used to track children’s developmental progress and identify any sources of concern. Pediatricians can then use the information obtained through the Cognoa app to inform meaningful diagnoses and treatment plans.
Autism spectrum disorder (ASD), delays in the acquisition of language and speech, and attention deficit/hyperactivity disorder, or ADHD/ADD, are among the conditions the app can help detect.
While early intervention is crucial in properly addressing these and other developmental issues, statistics show that there is often a significant lag in achieving an appropriate diagnosis. Sometimes that time lag can stretch into years, putting a child outside the optimum window for intervention and treatment to be most successful.
The app changes all that, putting initial screening power into the hands of families themselves. A parent using the app responds to a series of basic questions about a child’s behavior and uploads short videos documenting it. The app then applies standard clinical diagnostic criteria based on algorithms produced by research at Harvard Medical School and Stanford University School of Medicine.
The risk assessment produced then gives parents and their child’s physician a head start in crafting an individualized diagnosis and an ongoing plan for prioritizing the child’s development.
SAP’s Partnership with Cognoa Provides Important Employee Benefit
SAP’s Partnership with Cognoa Provides Important Employee Benefit
Silicon Valley-based Cognoa uses an artificial intelligence-guided platform that serves as an effective early screening method to help detect autism and other developmental delays. The platform is based on extensive research conducted at Harvard Medical School, Stanford University School of Medicine, and other prestigious institutions. Cognoacurrently offers its clinically validated app to…
Cognoa Autism Screening Devices Earn FDA Breakthrough Status
Cognoa Autism Screening Devices Earn FDA Breakthrough Status
In February 2019, Silicon Valley digital therapeutics maker Cognoa announced that it had received the official United States Food and Drug Administration breakthrough device designations for its autism diagnostic devices. As part of Cognoa’s precision healthcare delivery platform, these devices can be used by parents for initial screenings, and by clinicians in diagnostic work with young children.
Early Developmental Intervention Builds Stronger Neural Connections
Early Developmental Intervention Builds Stronger Neural Connections
Brain article Photo by Alina Grubnyak on Unsplash
A Palo Alto, California-based company, Cognoahas emerged as a leader in the development of artificial intelligence-powered diagnostics focused on early childhood development. Cognoa’s algorithms, currently in use by experienced clinicians and by targeted groups of parents through their employers or insurers, are based on research conducted at…
Cognoa - AI-Informed Solutions That Benefit Employers and Employees
Cognoa – AI-Informed Solutions That Benefit Employers and Employees
Cognoa
Image: Cognoa.com
A digital diagnostics firm, Cognoa employs AI- and physician-informed algorithms to help screen and identify risk of developmental delays in children from 18 months through 5 years of age. Cognoa also provides research-backed ways of addressing sleep issues. Cognoa provides companies with efficient ways of supporting employees who care for young children.
Cognoa Recognized by FDA through “Breakthrough Device” Designation
Cognoa Recognized by FDA through “Breakthrough Device” Designation
Focused on digital behavioral health solutions, Cognoa has designed state-of-the-art digital therapeutic and digital diagnostic devices. The Cognoa precision health platform helps parents identify children’s developmental delays, as well as take steps to improve their quality of sleep. In February 2019, Cognoa announced that its lead offerings had received Breakthrough Device designation from the…
Studies Examine AI-based Tool Used in Early Identification of Autism
Studies Examine AI-based Tool Used in Early Identification of Autism
Cognoa
Image: Cognoa.com
Based in Palo Alto, California, Cognoaoffers artificial intelligence-based diagnostics and therapies designed to identify and treat behavioral conditions in children at a younger age. In 2018, Autism Research and the Journal of the American Medical Informatics Association (JAMIA) published studies that evaluated the performance of Cognoa’s AI-based tool and its ability…
Cambia Adopts Cognoa App to Screen for Developmental Delays
Cambia Adopts Cognoa App to Screen for Developmental Delays
Cognoa
Image: Cognoa.com
Cognoa, a company based in Silicon Valley, is developing artificial intelligence-driven diagnostic applications that can identify risk for a range of developmental delays in children. Early in 2019, Cambia Health Solutions began incorporating the Cognoa platform in its subsidiary healthcare plan structure.
Cambia Health Solutions will facilitate employers’ ability to offer…
Cognoa Named a Finalist for First The Bump Best of Baby Tech Awards
Cognoa Named a Finalist for First The Bump Best of Baby Tech Awards
Cognoa
Image: Cognoa.com
A consumer healthcare organization located in Palo Alto, California, Cognoa makes child development applications based on machine learning research conducted at Harvard Medical School and Stanford Medical School. Cognoa’s success in the healthcare solutions field enabled it to become a finalist for the first annual The Bump Best of Baby Tech Awards.
Cognoa is a Palo Alto, California, healthcare company focused on child development. Parents can send video footage of their child to the experts at Cognoa, who evaluate the child and screen for developmental delays or disabilities.
Parenting style can have a significant impact on the development of a child. Authoritarian parenting and authoritative parenting are similar…
